Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin crossover study in hypertrophic cardiomyopathy
ACTRN12611000495921Phase 2Not yet recruiting
- Sponsor
- Professor Joseph Selvanayagam
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of metformin in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by Professor Joseph Selvanayagam. Primary endpoint: Phosphocreatine to adenosine triphosphate ratio. Planned start Jul 2011; status: not yet recruiting.
02
Drugs
metformin
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on ACTRN12611000495921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000495921.